To take the MLKL-mRNA approach a step closer from bench to bedside, we demonstrated that the new anti-tumor mRNA therapy can also elicit protective anti-tumor responses against a human lymphoma in mice with a reconstituted human adaptive immune system. The gene discussed is MLKL; the disease is neoplasm.